HSBC Cuts Biogen Rating as MS Business Weakens
HSBC downgraded Biogen to Reduce, citing weakness in its multiple sclerosis business, margin pressure, and limited near-term earnings growth.
/ 1664 items
#XY↓
FDA Approves Amneal’s New Epinephrine Injection Vials for Emergency Care
The FDA has approved Amneal Pharmaceuticals’ new single- and multi-dose epinephrine vials, expanding access to a critical emergency medicine used for allergic reactions and septic shock in hospitals and acute care settings.
J&J's MajesTEC-3 Data Creates Competitive Landscape in Multiple Myeloma Treatment
Johnson & Johnson's (JNJ) Tecvayli-Darzalex combination shows strong Phase 3 results in multiple myeloma, creating competitive pressure for CAR-T therapies like Carvykti (LEGN) while offering new treatment options.
Cronos Group Expands into Netherlands with CanAdelaar Acquisition
Cronos Group acquires CanAdelaar, the leading cannabis company in the Netherlands’ Wietexperiment, strengthening its European footprint and borderless product strategy.
Alcon Raises Its Offer to Acquire Staar Surgical for $1.6 Billion
Alcon boosts its bid for Staar Surgical to $30.75 per share, valuing the company at $1.6 billion. The updated offer adds $150M in equity value and aims to secure shareholder approval after months of resistance.
Teleflex Sells Three Business Units for $2.03 Billion to Sharpen Strategic Focus
Teleflex announces $2.03B sale of Acute Care, Interventional Urology, and OEM businesses to streamline operations and focus on core medical technology markets while returning capital to shareholders.